Table 1.
Feature | Training set (n = 189) | Validation set (n = 815) | p Value | |||
---|---|---|---|---|---|---|
Number of patients | Percent | Number of patients | Percent | Percent missing | ||
Gender | ||||||
Male | 85 | 45 | 369 | 45 | 0 | 0.91 |
Female | 104 | 55 | 446 | 55 | ||
Diagnosis group | ||||||
1.0 | 52 | 27 | 173 | 21 | < 1 | < 0.001* |
2.0 | 34 | 18 | 74 | 9 | ||
3.0 | 103 | 55 | 567 | 70 | ||
Visceral metastases | ||||||
Yes | 114 | 60 | 325 | 40 | 6 | < 0.001* |
No | 75 | 40 | 441 | 54 | ||
Lymph node metastases | ||||||
Yes | 36 | 19 | 169 | 21 | 62 | < 0.001* |
No | 153 | 81 | 143 | 18 | ||
Number of bone metastases | ||||||
Solitary | 55 | 29 | 123 | 15 | 3 | < 0.001* |
Multiple | 134 | 71 | 666 | 82 | ||
Pathologic fracture | ||||||
Complete | 84 | 44 | 614 | 75 | < 1 | < 0.001* |
Impending | 105 | 56 | 196 | 24 | ||
ECOG performance status | ||||||
0, 1, or 2 | 93 | 49 | 558 | 68 | 0 | < 0.001* |
3 or 4 | 96 | 51 | 257 | 32 | ||
Survival > 1 months | ||||||
Yes | 173 | 92 | 622 | 87 | 0 | < 0.001* |
No | 16 | 8 | 193 | 13 | ||
Survival > 6 months | ||||||
Yes | 111 | 59 | 372 | 46 | 0 | 0.001* |
No | 78 | 41 | 443 | 54 |
*Distributions are significantly different between the training and validation sets by the chi square method; Percent missing = the proportion of unknown or missing data in the validation set; ECOG = Eastern Cooperative Oncology Group.